What Section 232 Means for Your Cross-Border Lane
On July 31, a 100% tariff lands on patented pharmaceutical imports into the United States. Companies with smaller import volumes have until September 29 before the same rate applies to them. Either date changes the math on where you manufacture and how you move product across North America, and it changes it now, not next year.
The Tariff Is the Trigger, Not the Whole Story
Section 232 tariffs on patented pharmaceutical imports are set at 100%, phased in on a tiered schedule: major pharmaceutical companies face the rate starting July 31, 2026, and everyone else follows on September 29. The tariffs are already accelerating a shift that was underway before this announcement: pharmaceutical manufacturers moving production and sourcing closer to home, onshoring and reshoring across Canada, the US, and Mexico instead of relying on longer international supply chains.
That shift changes the shape of the freight itself. Less product is arriving from overseas. More of it is moving domestically and across the Canada-US-Mexico corridor. If your company is part of that shift, even partially, the lane your product travels on has changed, and so has what you need from a carrier.
It’s tempting to treat this as a finance and sourcing problem and leave logistics out of the conversation until the ink is dry on a new supplier agreement. That’s a mistake. A sourcing decision made this month still has to move through a physical supply chain a few months from now, and that supply chain has to be GDP-compliant the day it starts moving, not eventually.
Why This Changes Your Carrier Math
A carrier that has only ever handled straightforward domestic freight is not the same as one with GDP-compliant capacity built specifically for pharmaceutical cargo across all three North American borders. Onshoring doesn’t remove the compliance burden; it just moves it closer to home. Every cross-border movement between Canada, the US, and Mexico still needs the same documentation, the same temperature control, the same audit trail you’d expect on any international pharmaceutical shipment.
This is also where a lot of carrier relationships get exposed. A carrier that’s strong on one leg of the Canada-US-Mexico triangle and thin on the other two forces you to manage two or three vendor relationships just to cover a route that used to be one overseas shipment. Every added handoff is another point where temperature control, documentation, or timing can fail, and another place an auditor can find a gap.
The practical question for this quarter isn’t whether your supply chain needs to move differently. It’s whether the carrier you have today can actually handle it, right now, not after a ramp-up period you don’t have time for.
Three Questions to Ask Your Carrier This Week
- Can they show GDP and GMP-audited capacity across Canada, the US, and Mexico, not just one or two of the three?
- If your volume shifts from international import lanes to domestic or cross-border ones, can they absorb that volume without a scramble, and can they show you what that ramp-up actually looks like?
- Is their documentation ready for an audit today, not after they’ve had time to prepare for one?
If the answer to any of those is uncertain, that uncertainty is the actual cost of this tariff, not the 100% rate itself. The rate is public and known. What isn’t known yet, for a lot of manufacturers, is whether their carrier can actually execute on the lane this tariff is pushing them toward.
“This tariff is accelerating something that was already happening: pharmaceutical manufacturing coming back to North America. We built our pharma division for exactly this kind of shift, and we’d rather be ready a year early than a month late.” ~ Aldo DeCarolis, CEO, Vitesse Transport.
Vitesse has moved freight across Canada, the US, and Mexico for 25 years. Our dedicated pharmaceutical division, GDP and GMP-certified and built specifically for temperature-sensitive cargo, launched in 2020 and has spent the six years since proving that a single carrier can handle all three borders without the coverage gaps a patchwork of regional carriers creates. That combination, decades of cross-border trucking experience plus focused pharma compliance, is exactly what this shift is asking manufacturers to have in place.
